EQS Group-Media / 2020-03-06 / 19:00
*Media Release*
*Medacta Announces FDA Clearance for Mecta-C Stand Alone Anterior Cervical
Interbody Fusion Device*
_CASTEL SAN PIETRO_, _06 March 2020 _- Medacta is proud to announce the
clearance from the U.S. Food and Drug Administration (FDA) for the Mecta-C
Stand Alone platform for anterior cervical discectomy and fusion procedures
(ACDF). Mecta-C Stand Alone is indicated for use from C2 to T1 in skeletally
mature patients suffering from degenerative disc disease.
The platform incorporates the benefits of an anterior plate with a versatile
screw system, thus requiring no additional fixation. The modular design is
an important characteristic of the Mecta-C Stand Alone system, allowing the
surgeon to intraoperatively select four plating options - Flush, Trio,
Hybrid and Quattro - to best treat various patient needs and anatomies. Each
option allows for either a locking screw or lag screw feature, and includes
an easy-to-use locking mechanism that provides surgeons with unique
intraoperative versatility.
The Mecta-C Stand Alone anterior cervical interbody fusion devices are
offered in TiPEEK, Medacta's plasma-sprayed titanium coating that provides
an added value to improve stability and increase the migration resistance.
Mecta-C Stand Alone is an indication-specific interbody fusion device which
enriches the suite of 360° cervical solutions to provide a treatment to
numerous cervical spine disorders.
For more information on Medacta Spine visit spine.medacta.com [1].
*Contact*
Medacta International SA
Gianluca Olgiati
Senior Director Global Marketing
Phone: +41 91 696 60 60
media@medacta.ch
*About Medacta*
Medacta is an international company specializing in the design and
production of innovative orthopaedic products and the development of
accompanying surgical techniques for joint replacement, spine surgery, and
sports medicine. Established in 1999 in Switzerland, Medacta's products and
surgical techniques are characterized by innovation. Medacta is a pioneer in
developing new offerings on the basis of minimally invasive surgical
techniques, in particular its Anterior Minimally Invasive Surgery ("AMIS")
technique for hip replacements. Medacta has leveraged its orthopaedic
expertise and comprehensive understanding of the human body to develop the
sophisticated "MySolutions" technology, which offers surgeons highly
personalized pre-operative planning and implant placement methodologies by
creating advanced personalized kinematic models and 3D planning tools for
use in hip, knee, shoulder and spine procedures.
Issuer: Medacta Group SA
Key word(s): Health
End of Corporate News
Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 91 696 6060
E-mail: info@medacta.ch, investor.relations@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 991689
End of News EQS Group Media
991689 2020-03-06
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=d8972af999979a214b7de3d0ef17981b&application_id=991689&site_id=vwd&application_name=news
(END) Dow Jones Newswires
March 06, 2020 13:00 ET (18:00 GMT)
